GW Pharmaceuticals Articles

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results

7 May 2013

Bayer's PAH drug candidate riociguat gets US priority review; Sativex rescheduled in UK

8 April 2013

Almirall could pull Sativex from German market due to inadequate pricing

20 March 2013

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14 October 2012

News briefs: Copaxone patent ruling; German Sativex backing; Depomed licenses Zipsor

24 June 2012

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress

9 May 2012

No proof of added benefit of Sativex, says German IQWiG

17 April 2012

GW Pharma and Almirall extend Sativex deal to Mexico

15 March 2012

GW Pharma’s Sativex cleared in Austria

7 February 2012

Spain’s Almirall launches Sativex and gets OK for Actikerall in Germany

6 July 2011

German approval for GW and Almirall’s Sativex for spasticity due to MS

27 May 2011

Novartis drops Ph III Tasigna trial for GIST; in-licenses Sativex; and reports new Gilenya data

11 April 2011

GW Pharma initiates Ph IIa study of cannabinoid in diabetes

1 October 2010

Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche

28 July 2010

First cannabis-derived medicine comes to market, but there are a few other hurdles to surmount

24 June 2010

GW Pharma debuts first Rx cannabis medicine, Sativex, in the UK; NICE gives preliminary backing for Amgen’s osteo drug Prolia

21 June 2010

Regulators in UK and Spain confirm Almirall/GW’s Sativex is approvable

20 May 2010

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end